« Report from C&E News |
| Maitotoxin Revisited »
April 26, 2010
Charles River Buys WuXi
I don't think we saw this one coming: Charles River Labs has announced that they're buying WuXi PharmaTech. They're paying about a 28% premium over Friday's closing stock price - Charles River's CEO will stay on, and WuXi's founder (Li Ge) will serve as executive VP under him.
Charles River, which is strong in the animal-testing end of the business, has apparently decided that Wu Xi is one of their biggest competitors (I'd agree) and has decided to try to stake out a leading position in the whole contract-research space. It's interesting to me that the folks at Wu Xi bought into this reasoning as well, although (since they're a publicly traded company here in the US), a lucrative stock offer can be its own argument. One now wonders, though, about the company's statements on re-staffing some of their US labs when economic conditions improve. . .
+ TrackBacks (0) | Category: Animal Testing | Business and Markets | Drug Assays | Drug Development
POST A COMMENT
- RELATED ENTRIES
- Grad School in Chemistry - The Mental Health Aspects
- Oxidizing Alcohols - With Water
- Anti-GMO. Until This Week.
- Science Fraud and Legal Action
- An Article That Shows What Med-Chem Is Like?
- Deal of the Year?
- Overselling p53 Drugs